JP2009541205A - Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用 - Google Patents

Info

Publication number

JP2009541205A

JP2009541205A JP2009500513A JP2009500513A JP2009541205A JP 2009541205 A JP2009541205 A JP 2009541205A JP 2009500513 A JP2009500513 A JP 2009500513A JP 2009500513 A JP2009500513 A JP 2009500513A JP 2009541205 A JP2009541205 A JP 2009541205A

Authority

JP

Japan

Prior art keywords

substituted

unsubstituted

compound

alkyl

disease

Prior art date

2006-03-16

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims abstract description 360
• 102100037602 P2X purinoceptor 7 Human genes 0.000 title description 4
• 101710189965 P2X purinoceptor 7 Proteins 0.000 title description 4
• 208000002193 Pain Diseases 0.000 claims abstract description 36
• 238000011282 treatment Methods 0.000 claims abstract description 36
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 29
• 230000036407 pain Effects 0.000 claims abstract description 23
• 241000124008 Mammalia Species 0.000 claims abstract description 21
• 208000004296 neuralgia Diseases 0.000 claims abstract description 21
• 206010061218 Inflammation Diseases 0.000 claims abstract description 19
• 230000004054 inflammatory process Effects 0.000 claims abstract description 19
• 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 17
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 16
• 208000021722 neuropathic pain Diseases 0.000 claims abstract description 11
• 230000002265 prevention Effects 0.000 claims abstract description 11
• 206010019233 Headaches Diseases 0.000 claims abstract description 9
• 231100000869 headache Toxicity 0.000 claims abstract description 9
• 206010065390 Inflammatory pain Diseases 0.000 claims abstract description 8
• 208000004371 toothache Diseases 0.000 claims abstract description 8
• 208000006561 Cluster Headache Diseases 0.000 claims abstract description 7
• 208000019695 Migraine disease Diseases 0.000 claims abstract description 7
• 206010043269 Tension headache Diseases 0.000 claims abstract description 7
• 208000008548 Tension-Type Headache Diseases 0.000 claims abstract description 7
• 208000018912 cluster headache syndrome Diseases 0.000 claims abstract description 7
• 206010027599 migraine Diseases 0.000 claims abstract description 7
• 208000005298 acute pain Diseases 0.000 claims abstract description 6
• 208000000094 Chronic Pain Diseases 0.000 claims abstract description 5
• 208000014674 injury Diseases 0.000 claims abstract 2
• -1 sulfate ester Chemical class 0.000 claims description 136
• 125000003118 aryl group Chemical group 0.000 claims description 102
• 125000000217 alkyl group Chemical group 0.000 claims description 86
• 239000000203 mixture Substances 0.000 claims description 82
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 79
• 238000000034 method Methods 0.000 claims description 73
• 125000001072 heteroaryl group Chemical group 0.000 claims description 60
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 53
• 125000002252 acyl group Chemical group 0.000 claims description 50
• 229910052739 hydrogen Inorganic materials 0.000 claims description 48
• 239000001257 hydrogen Substances 0.000 claims description 48
• 125000001424 substituent group Chemical group 0.000 claims description 46
• 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 42
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 41
• 125000000547 substituted alkyl group Chemical group 0.000 claims description 38
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 36
• 201000010099 disease Diseases 0.000 claims description 36
• 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 35
• 125000003545 alkoxy group Chemical group 0.000 claims description 33
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 30
• 125000003396 thiol group Chemical group [H]S* 0.000 claims description 30
• 125000004404 heteroalkyl group Chemical group 0.000 claims description 29
• 125000004442 acylamino group Chemical group 0.000 claims description 28
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 28
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 27
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 27
• 150000001540 azides Chemical class 0.000 claims description 24
• 238000006243 chemical reaction Methods 0.000 claims description 24
• 125000003107 substituted aryl group Chemical group 0.000 claims description 23
• 229910052731 fluorine Inorganic materials 0.000 claims description 22
• 125000004104 aryloxy group Chemical group 0.000 claims description 21
• 125000003282 alkyl amino group Chemical group 0.000 claims description 19
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 19
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 19
• 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims description 19
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 19
• 239000000651 prodrug Substances 0.000 claims description 19
• 229940002612 prodrug Drugs 0.000 claims description 19
• 150000003457 sulfones Chemical class 0.000 claims description 19
• 125000004947 alkyl aryl amino group Chemical group 0.000 claims description 18
• 125000004414 alkyl thio group Chemical group 0.000 claims description 18
• 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 18
• 229910052796 boron Inorganic materials 0.000 claims description 18
• 125000004663 dialkyl amino group Chemical group 0.000 claims description 18
• 125000005553 heteroaryloxy group Chemical group 0.000 claims description 18
• 208000035475 disorder Diseases 0.000 claims description 17
• 125000001475 halogen functional group Chemical group 0.000 claims description 17
• 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 17
• 150000003462 sulfoxides Chemical class 0.000 claims description 17
• 229910052721 tungsten Inorganic materials 0.000 claims description 17
• 229910052727 yttrium Inorganic materials 0.000 claims description 17
• 208000023275 Autoimmune disease Diseases 0.000 claims description 16
• 125000005415 substituted alkoxy group Chemical group 0.000 claims description 16
• 239000002253 acid Substances 0.000 claims description 15
• 208000037765 diseases and disorders Diseases 0.000 claims description 15
• 150000003839 salts Chemical class 0.000 claims description 15
• 239000003814 drug Substances 0.000 claims description 14
• 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 14
• 230000001404 mediated effect Effects 0.000 claims description 14
• 125000000304 alkynyl group Chemical group 0.000 claims description 13
• 201000008482 osteoarthritis Diseases 0.000 claims description 13
• 125000004076 pyridyl group Chemical group 0.000 claims description 13
• 208000030886 Traumatic Brain injury Diseases 0.000 claims description 12
• 125000003342 alkenyl group Chemical group 0.000 claims description 12
• 239000012453 solvate Substances 0.000 claims description 12
• 230000009529 traumatic brain injury Effects 0.000 claims description 12
• SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 11
• 208000006673 asthma Diseases 0.000 claims description 11
• 229910052801 chlorine Inorganic materials 0.000 claims description 11
• 208000010125 myocardial infarction Diseases 0.000 claims description 11
• 208000020925 Bipolar disease Diseases 0.000 claims description 10
• 208000003251 Pruritus Diseases 0.000 claims description 10
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 10
• 238000009472 formulation Methods 0.000 claims description 10
• 230000000155 isotopic effect Effects 0.000 claims description 10
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
• 208000024891 symptom Diseases 0.000 claims description 10
• FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 9
• 208000018737 Parkinson disease Diseases 0.000 claims description 9
• 206010015037 epilepsy Diseases 0.000 claims description 9
• UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 9
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 9
• 208000023504 respiratory system disease Diseases 0.000 claims description 9
• 208000020431 spinal cord injury Diseases 0.000 claims description 9
• 208000011580 syndromic disease Diseases 0.000 claims description 9
• 206010020751 Hypersensitivity Diseases 0.000 claims description 8
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 8
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 8
• 150000002148 esters Chemical class 0.000 claims description 8
• 238000001727 in vivo Methods 0.000 claims description 8
• 125000005017 substituted alkenyl group Chemical group 0.000 claims description 8
• 125000004426 substituted alkynyl group Chemical group 0.000 claims description 8
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 7
• 206010028980 Neoplasm Diseases 0.000 claims description 7
• 206010003246 arthritis Diseases 0.000 claims description 7
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 7
• 201000011510 cancer Diseases 0.000 claims description 7
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 7
• 208000019901 Anxiety disease Diseases 0.000 claims description 6
• 208000030814 Eating disease Diseases 0.000 claims description 6
• 208000019454 Feeding and Eating disease Diseases 0.000 claims description 6
• 208000008589 Obesity Diseases 0.000 claims description 6
• 201000004681 Psoriasis Diseases 0.000 claims description 6
• 150000001408 amides Chemical class 0.000 claims description 6
• 230000036506 anxiety Effects 0.000 claims description 6
• 230000036772 blood pressure Effects 0.000 claims description 6
• 229910052794 bromium Inorganic materials 0.000 claims description 6
• 235000014632 disordered eating Nutrition 0.000 claims description 6
• 230000004064 dysfunction Effects 0.000 claims description 6
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
• 150000002632 lipids Chemical class 0.000 claims description 6
• 125000006217 methyl sulfide group Chemical group [H]C([H])([H])S* 0.000 claims description 6
• 201000006417 multiple sclerosis Diseases 0.000 claims description 6
• 235000020824 obesity Nutrition 0.000 claims description 6
• 230000008085 renal dysfunction Effects 0.000 claims description 6
• 201000000980 schizophrenia Diseases 0.000 claims description 6
• 208000019116 sleep disease Diseases 0.000 claims description 6
• 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 6
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 5
• 206010069632 Bladder dysfunction Diseases 0.000 claims description 5
• 208000034347 Faecal incontinence Diseases 0.000 claims description 5
• 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 5
• 206010046543 Urinary incontinence Diseases 0.000 claims description 5
• 230000001594 aberrant effect Effects 0.000 claims description 5
• 208000026935 allergic disease Diseases 0.000 claims description 5
• RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical group CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims description 5
• 208000028683 bipolar I disease Diseases 0.000 claims description 5
• 208000010877 cognitive disease Diseases 0.000 claims description 5
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
• 206010014599 encephalitis Diseases 0.000 claims description 5
• 230000009610 hypersensitivity Effects 0.000 claims description 5
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 5
• 230000000241 respiratory effect Effects 0.000 claims description 5
• 229940124530 sulfonamide Drugs 0.000 claims description 5
• 150000003456 sulfonamides Chemical class 0.000 claims description 5
• 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 4
• 208000014540 Functional gastrointestinal disease Diseases 0.000 claims description 4
• 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 4
• 230000002159 abnormal effect Effects 0.000 claims description 4
• 201000007637 bowel dysfunction Diseases 0.000 claims description 4
• 206010013990 dysuria Diseases 0.000 claims description 4
• 230000007803 itching Effects 0.000 claims description 4
• 230000003959 neuroinflammation Effects 0.000 claims description 4
• 210000002307 prostate Anatomy 0.000 claims description 4
• 208000036273 reactive airway disease Diseases 0.000 claims description 4
• 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims description 3
• 208000001640 Fibromyalgia Diseases 0.000 claims description 3
• 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 3
• 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 3
• 208000004983 Phantom Limb Diseases 0.000 claims description 3
• 206010056238 Phantom pain Diseases 0.000 claims description 3
• 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 3
• 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims description 3
• 150000007513 acids Chemical class 0.000 claims description 3
• 230000004913 activation Effects 0.000 claims description 3
• 150000005528 benzodioxoles Chemical class 0.000 claims description 3
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 3
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
• 150000002790 naphthalenes Chemical class 0.000 claims description 3
• 230000004770 neurodegeneration Effects 0.000 claims description 3
• 201000001119 neuropathy Diseases 0.000 claims description 3
• 125000003386 piperidinyl group Chemical group 0.000 claims description 3
• LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical class C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 claims description 3
• 230000001953 sensory effect Effects 0.000 claims description 3
• 206010044652 trigeminal neuralgia Diseases 0.000 claims description 3
• WITJHZRCLVXYCA-UHFFFAOYSA-N 3h-1,2-benzodioxepine Chemical class C1=CCOOC2=CC=CC=C21 WITJHZRCLVXYCA-UHFFFAOYSA-N 0.000 claims description 2
• 208000018569 Respiratory Tract disease Diseases 0.000 claims description 2
• 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
• 201000009961 allergic asthma Diseases 0.000 claims description 2
• 201000010105 allergic rhinitis Diseases 0.000 claims description 2
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
• 150000002545 isoxazoles Chemical class 0.000 claims description 2
• 230000000926 neurological effect Effects 0.000 claims description 2
• 125000004043 oxo group Chemical group O=* 0.000 claims description 2
• 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
• 206010029240 Neuritis Diseases 0.000 claims 5
• 230000007794 irritation Effects 0.000 claims 4
• 201000004983 autoimmune atherosclerosis Diseases 0.000 claims 3
• 201000004982 autoimmune uveitis Diseases 0.000 claims 3
• 230000007815 allergy Effects 0.000 claims 2
• YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims 2
• 208000012790 cranial neuralgia Diseases 0.000 claims 2
• 206010039083 rhinitis Diseases 0.000 claims 2
• 206010003399 Arthropod bite Diseases 0.000 claims 1
• 206010006482 Bronchospasm Diseases 0.000 claims 1
• 206010006784 Burning sensation Diseases 0.000 claims 1
• 206010008334 Cervicobrachial syndrome Diseases 0.000 claims 1
• 206010015150 Erythema Diseases 0.000 claims 1
• 208000001375 Facial Neuralgia Diseases 0.000 claims 1
• 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 claims 1
• 208000006877 Insect Bites and Stings Diseases 0.000 claims 1
• 206010049949 Intercostal neuralgia Diseases 0.000 claims 1
• 208000002472 Morton Neuroma Diseases 0.000 claims 1
• 208000020059 Morton neuralgia Diseases 0.000 claims 1
• 208000000112 Myalgia Diseases 0.000 claims 1
• 208000012902 Nervous system disease Diseases 0.000 claims 1
• 208000025966 Neurological disease Diseases 0.000 claims 1
• 206010068106 Occipital neuralgia Diseases 0.000 claims 1
• 206010036105 Polyneuropathy Diseases 0.000 claims 1
• 208000008765 Sciatica Diseases 0.000 claims 1
• 208000004078 Snake Bites Diseases 0.000 claims 1
• 208000003589 Spider Bites Diseases 0.000 claims 1
• 230000002146 bilateral effect Effects 0.000 claims 1
• 210000000481 breast Anatomy 0.000 claims 1
• 230000007885 bronchoconstriction Effects 0.000 claims 1
• 229960002504 capsaicin Drugs 0.000 claims 1
• 235000017663 capsaicin Nutrition 0.000 claims 1
• 230000035606 childbirth Effects 0.000 claims 1
• 231100000321 erythema Toxicity 0.000 claims 1
• 206010016766 flatulence Diseases 0.000 claims 1
• 201000005442 glossopharyngeal neuralgia Diseases 0.000 claims 1
• 208000027866 inflammatory disease Diseases 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 210000004914 menses Anatomy 0.000 claims 1
• 125000001624 naphthyl group Chemical group 0.000 claims 1
• 210000003254 palate Anatomy 0.000 claims 1
• IMACFCSSMIZSPP-UHFFFAOYSA-N phenacyl chloride Chemical compound ClCC(=O)C1=CC=CC=C1 IMACFCSSMIZSPP-UHFFFAOYSA-N 0.000 claims 1
• 208000019629 polyneuritis Diseases 0.000 claims 1
• 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
• 201000009890 sinusitis Diseases 0.000 claims 1
• 230000003393 splenic effect Effects 0.000 claims 1
• 239000003491 tear gas Substances 0.000 claims 1
• 230000000699 topical effect Effects 0.000 claims 1
• 231100000331 toxic Toxicity 0.000 claims 1
• 230000002588 toxic effect Effects 0.000 claims 1
• 230000008733 trauma Effects 0.000 claims 1
• 230000001154 acute effect Effects 0.000 abstract description 14
• 230000001684 chronic effect Effects 0.000 abstract description 5
• 230000002757 inflammatory effect Effects 0.000 abstract description 5
• 208000026278 immune system disease Diseases 0.000 abstract description 4
• 230000000670 limiting effect Effects 0.000 abstract description 4
• 208000024172 Cardiovascular disease Diseases 0.000 abstract description 2
• 230000008736 traumatic injury Effects 0.000 abstract 1
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 90
• 210000004027 cell Anatomy 0.000 description 54
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 34
• 239000007787 solid Substances 0.000 description 34
• 150000003254 radicals Chemical class 0.000 description 33
• 241001465754 Metazoa Species 0.000 description 32
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 31
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 31
• 229910052757 nitrogen Inorganic materials 0.000 description 31
• 102000005962 receptors Human genes 0.000 description 31
• 108020003175 receptors Proteins 0.000 description 31
• 239000000243 solution Substances 0.000 description 31
• 125000005843 halogen group Chemical group 0.000 description 29
• 241000700159 Rattus Species 0.000 description 27
• 238000012360 testing method Methods 0.000 description 27
• 150000002431 hydrogen Chemical class 0.000 description 25
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
• 239000000047 product Substances 0.000 description 23
• 125000005309 thioalkoxy group Chemical group 0.000 description 23
• 230000000694 effects Effects 0.000 description 22
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 20
• 125000004432 carbon atom Chemical group C* 0.000 description 19
• 239000011541 reaction mixture Substances 0.000 description 16
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
• 210000004369 blood Anatomy 0.000 description 15
• 239000008280 blood Substances 0.000 description 15
• 238000002474 experimental method Methods 0.000 description 14
• 230000005764 inhibitory process Effects 0.000 description 14
• 125000005346 substituted cycloalkyl group Chemical group 0.000 description 14
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 13
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
• 125000004423 acyloxy group Chemical group 0.000 description 13
• 239000000126 substance Substances 0.000 description 13
• 235000019439 ethyl acetate Nutrition 0.000 description 12
• 229910052736 halogen Inorganic materials 0.000 description 12
• 229910052740 iodine Inorganic materials 0.000 description 12
• 210000002540 macrophage Anatomy 0.000 description 12
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
• 230000002829 reductive effect Effects 0.000 description 12
• 125000004429 atom Chemical group 0.000 description 11
• 210000000269 carotid artery external Anatomy 0.000 description 11
• 150000002367 halogens Chemical class 0.000 description 11
• 229910052760 oxygen Inorganic materials 0.000 description 11
• 125000005296 thioaryloxy group Chemical group 0.000 description 11
• 239000003981 vehicle Substances 0.000 description 11
• AWJJLYZBWRIBCZ-UGTJMOTHSA-N 3'-O-(4-Benzoyl)benzoyl ATP Chemical compound O([C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)N1C=2N=CN=C(C=2N=C1)N)C(=O)C(C=C1)=CC=C1C(=O)C1=CC=CC=C1 AWJJLYZBWRIBCZ-UGTJMOTHSA-N 0.000 description 10
• KCYWNAAVPRMMLP-UHFFFAOYSA-N 5-nitroisochromen-1-one Chemical compound C1=COC(=O)C2=C1C([N+](=O)[O-])=CC=C2 KCYWNAAVPRMMLP-UHFFFAOYSA-N 0.000 description 10
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 10
• 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 10
• 125000005842 heteroatom Chemical group 0.000 description 10
• 238000002360 preparation method Methods 0.000 description 10
• 239000002904 solvent Substances 0.000 description 10
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
• 125000005323 thioketone group Chemical group 0.000 description 10
• ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 9
• 229930194542 Keto Natural products 0.000 description 9
• 125000000468 ketone group Chemical group 0.000 description 9
• 239000002609 medium Substances 0.000 description 9
• 210000005087 mononuclear cell Anatomy 0.000 description 9
• 210000005036 nerve Anatomy 0.000 description 9
• 125000005500 uronium group Chemical group 0.000 description 9
• OVOJUAKDTOOXRF-UHFFFAOYSA-N 2,4-dinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O OVOJUAKDTOOXRF-UHFFFAOYSA-N 0.000 description 8
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
• ULHRKLSNHXXJLO-UHFFFAOYSA-L Yo-Pro-1 Chemical compound [I-].[I-].C1=CC=C2C(C=C3N(C4=CC=CC=C4O3)C)=CC=[N+](CCC[N+](C)(C)C)C2=C1 ULHRKLSNHXXJLO-UHFFFAOYSA-L 0.000 description 8
• 239000000556 agonist Substances 0.000 description 8
• 150000001412 amines Chemical class 0.000 description 8
• 125000004122 cyclic group Chemical group 0.000 description 8
• 125000000392 cycloalkenyl group Chemical group 0.000 description 8
• 239000002158 endotoxin Substances 0.000 description 8
• 229920006008 lipopolysaccharide Polymers 0.000 description 8
• 229910052717 sulfur Inorganic materials 0.000 description 8
• 239000000725 suspension Substances 0.000 description 8
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 7
• 206010046851 Uveitis Diseases 0.000 description 7
• 125000002947 alkylene group Chemical group 0.000 description 7
• XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 7
• 230000037396 body weight Effects 0.000 description 7
• 229940079593 drug Drugs 0.000 description 7
• 125000000524 functional group Chemical group 0.000 description 7
• 125000004446 heteroarylalkyl group Chemical group 0.000 description 7
• 125000000623 heterocyclic group Chemical group 0.000 description 7
• 238000004128 high performance liquid chromatography Methods 0.000 description 7
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 7
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 7
• 229920000053 polysorbate 80 Polymers 0.000 description 7
• 230000004044 response Effects 0.000 description 7
• 239000007858 starting material Substances 0.000 description 7
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
• 239000012981 Hank's balanced salt solution Substances 0.000 description 6
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
• 229930182555 Penicillin Natural products 0.000 description 6
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
• 239000012980 RPMI-1640 medium Substances 0.000 description 6
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
• 230000002378 acidificating effect Effects 0.000 description 6
• 125000001931 aliphatic group Chemical group 0.000 description 6
• 230000015572 biosynthetic process Effects 0.000 description 6
• 239000012267 brine Substances 0.000 description 6
• 235000010418 carrageenan Nutrition 0.000 description 6
• 239000000679 carrageenan Substances 0.000 description 6
• 229920001525 carrageenan Polymers 0.000 description 6
• 229940113118 carrageenan Drugs 0.000 description 6
• 150000001768 cations Chemical class 0.000 description 6
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 6
• 229960005542 ethidium bromide Drugs 0.000 description 6
• 125000001183 hydrocarbyl group Chemical group 0.000 description 6
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
• 238000002347 injection Methods 0.000 description 6
• 239000007924 injection Substances 0.000 description 6
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 6
• 239000010410 layer Substances 0.000 description 6
• 210000003141 lower extremity Anatomy 0.000 description 6
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
• 238000005259 measurement Methods 0.000 description 6
• 229940049954 penicillin Drugs 0.000 description 6
• 239000002953 phosphate buffered saline Substances 0.000 description 6
• 239000011148 porous material Substances 0.000 description 6
• 239000011734 sodium Substances 0.000 description 6
• 239000011780 sodium chloride Substances 0.000 description 6
• 229910052938 sodium sulfate Inorganic materials 0.000 description 6
• 235000011152 sodium sulphate Nutrition 0.000 description 6
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
• 238000003756 stirring Methods 0.000 description 6
• 238000001356 surgical procedure Methods 0.000 description 6
• 238000003786 synthesis reaction Methods 0.000 description 6
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 6
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
• 201000001320 Atherosclerosis Diseases 0.000 description 5
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
• 230000017531 blood circulation Effects 0.000 description 5
• 201000002491 encephalomyelitis Diseases 0.000 description 5
• 210000003414 extremity Anatomy 0.000 description 5
• 239000000706 filtrate Substances 0.000 description 5
• 238000001914 filtration Methods 0.000 description 5
• 238000001990 intravenous administration Methods 0.000 description 5
• 210000002429 large intestine Anatomy 0.000 description 5
• 239000003921 oil Substances 0.000 description 5
• 238000002953 preparative HPLC Methods 0.000 description 5
• 239000000741 silica gel Substances 0.000 description 5
• 229910002027 silica gel Inorganic materials 0.000 description 5
• 229960005322 streptomycin Drugs 0.000 description 5
• 210000001519 tissue Anatomy 0.000 description 5
• 239000003039 volatile agent Substances 0.000 description 5
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 4
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• 208000004454 Hyperalgesia Diseases 0.000 description 4
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
• 241000699670 Mus sp. Species 0.000 description 4
• 206010030113 Oedema Diseases 0.000 description 4
• 206010033799 Paralysis Diseases 0.000 description 4
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 125000005907 alkyl ester group Chemical group 0.000 description 4
• 150000008064 anhydrides Chemical class 0.000 description 4
• 238000010171 animal model Methods 0.000 description 4
• 230000003110 anti-inflammatory effect Effects 0.000 description 4
• 239000012298 atmosphere Substances 0.000 description 4
• 230000001363 autoimmune Effects 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
• 210000004004 carotid artery internal Anatomy 0.000 description 4
• 210000001072 colon Anatomy 0.000 description 4
• 230000004069 differentiation Effects 0.000 description 4
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
• 239000002552 dosage form Substances 0.000 description 4
• 230000002526 effect on cardiovascular system Effects 0.000 description 4
• 235000013305 food Nutrition 0.000 description 4
• 230000006870 function Effects 0.000 description 4
• PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 4
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 4
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 4
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
• 238000002955 isolation Methods 0.000 description 4
• 239000011777 magnesium Substances 0.000 description 4
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• 229920000728 polyester Polymers 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 125000006239 protecting group Chemical group 0.000 description 4
• 230000002285 radioactive effect Effects 0.000 description 4
• 239000000523 sample Substances 0.000 description 4
• 229920006395 saturated elastomer Polymers 0.000 description 4
• 210000003497 sciatic nerve Anatomy 0.000 description 4
• 229940124597 therapeutic agent Drugs 0.000 description 4
• 230000001225 therapeutic effect Effects 0.000 description 4
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
• 238000005303 weighing Methods 0.000 description 4
• RYZFNOCRYSHBIH-UHFFFAOYSA-N 2-[2-(dimethylamino)ethenyl]-3-nitrobenzoic acid Chemical compound CN(C)C=CC1=C(C(O)=O)C=CC=C1[N+]([O-])=O RYZFNOCRYSHBIH-UHFFFAOYSA-N 0.000 description 3
• AZBFOENSKLAYKT-UHFFFAOYSA-N 2-[4-chloro-3-(trifluoromethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=C(Cl)C(C(F)(F)F)=C1 AZBFOENSKLAYKT-UHFFFAOYSA-N 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• 108091006146 Channels Proteins 0.000 description 3
• 238000002965 ELISA Methods 0.000 description 3
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 239000007995 HEPES buffer Substances 0.000 description 3
• 102100037850 Interferon gamma Human genes 0.000 description 3
• 108010074328 Interferon-gamma Proteins 0.000 description 3
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
• JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
• 241000699666 Mus <mouse, genus> Species 0.000 description 3
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 3
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 3
• 229940024606 amino acid Drugs 0.000 description 3
• 235000001014 amino acid Nutrition 0.000 description 3
• 150000001413 amino acids Chemical class 0.000 description 3
• 239000005557 antagonist Substances 0.000 description 3
• 210000001367 artery Anatomy 0.000 description 3
• 125000001769 aryl amino group Chemical group 0.000 description 3
• 239000002585 base Substances 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 229910052799 carbon Inorganic materials 0.000 description 3
• 210000001168 carotid artery common Anatomy 0.000 description 3
• 125000001309 chloro group Chemical group Cl* 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000004440 column chromatography Methods 0.000 description 3
• 239000000975 dye Substances 0.000 description 3
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 3
• 238000011156 evaluation Methods 0.000 description 3
• 230000005284 excitation Effects 0.000 description 3
• 239000012467 final product Substances 0.000 description 3
• GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthene Chemical compound C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 3
• 125000001153 fluoro group Chemical group F* 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 239000008103 glucose Substances 0.000 description 3
• 210000005260 human cell Anatomy 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 150000002500 ions Chemical class 0.000 description 3
• 229960002725 isoflurane Drugs 0.000 description 3
• 210000004731 jugular vein Anatomy 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 239000000314 lubricant Substances 0.000 description 3
• 229910052749 magnesium Inorganic materials 0.000 description 3
• 235000019359 magnesium stearate Nutrition 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 210000003205 muscle Anatomy 0.000 description 3
• 230000002981 neuropathic effect Effects 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 239000012044 organic layer Substances 0.000 description 3
• 230000008823 permeabilization Effects 0.000 description 3
• 229910052700 potassium Inorganic materials 0.000 description 3
• 239000011591 potassium Substances 0.000 description 3
• 235000018102 proteins Nutrition 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 108090000623 proteins and genes Proteins 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 230000011514 reflex Effects 0.000 description 3
• 238000010992 reflux Methods 0.000 description 3
• 210000003491 skin Anatomy 0.000 description 3
• 238000003797 solvolysis reaction Methods 0.000 description 3
• 238000006467 substitution reaction Methods 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 239000012730 sustained-release form Substances 0.000 description 3
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
• 239000011534 wash buffer Substances 0.000 description 3
• OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 2
• UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
• LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
• BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 2
• FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 2
• HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
• MFJCPDOGFAYSTF-UHFFFAOYSA-N 1H-isochromene Chemical compound C1=CC=C2COC=CC2=C1 MFJCPDOGFAYSTF-UHFFFAOYSA-N 0.000 description 2
• GWGBNENHEGYJSN-UHFFFAOYSA-N 2,4-dinitrobenzenesulfonic acid;hydrate Chemical compound O.OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O GWGBNENHEGYJSN-UHFFFAOYSA-N 0.000 description 2
• MMYBPFLEDCZNET-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yl)-5-nitroisoquinolin-1-one Chemical compound C1N(CC2)CCC2C1N(C1=O)C=CC2=C1C=CC=C2[N+](=O)[O-] MMYBPFLEDCZNET-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• WGOCZWDCSUBRSL-UHFFFAOYSA-N 2-[2-fluoro-3-(trifluoromethyl)phenyl]-n-[2-(4-methylpyridin-3-yl)-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=NC=C1N1C(=O)C2=CC=CC(NC(=O)CC=3C(=C(C=CC=3)C(F)(F)F)F)=C2C=C1 WGOCZWDCSUBRSL-UHFFFAOYSA-N 0.000 description 2
• XFLVJVHUDXFTPE-UHFFFAOYSA-N 2-[4-chloro-3-(trifluoromethyl)phenyl]-n-(2-cyclobutyl-1-oxoisoquinolin-5-yl)acetamide Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(CC(=O)NC=2C3=C(C(N(C4CCC4)C=C3)=O)C=CC=2)=C1 XFLVJVHUDXFTPE-UHFFFAOYSA-N 0.000 description 2
• GEDNZGXPXDIUBD-UHFFFAOYSA-N 2-[4-chloro-3-(trifluoromethyl)phenyl]-n-[2-(2-fluoropyridin-3-yl)-1-oxoisoquinolin-5-yl]acetamide Chemical compound FC1=NC=CC=C1N1C(=O)C2=CC=CC(NC(=O)CC=3C=C(C(Cl)=CC=3)C(F)(F)F)=C2C=C1 GEDNZGXPXDIUBD-UHFFFAOYSA-N 0.000 description 2
• PUOHBLZEPBJLAT-UHFFFAOYSA-N 2-[4-chloro-3-(trifluoromethyl)phenyl]-n-[2-(2-methoxypyridin-3-yl)-1-oxoisoquinolin-5-yl]acetamide Chemical compound COC1=NC=CC=C1N1C(=O)C2=CC=CC(NC(=O)CC=3C=C(C(Cl)=CC=3)C(F)(F)F)=C2C=C1 PUOHBLZEPBJLAT-UHFFFAOYSA-N 0.000 description 2
• YAUDWMVXNVFABR-UHFFFAOYSA-N 2-[4-chloro-3-(trifluoromethyl)phenyl]-n-[2-(2-methylpyridin-3-yl)-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=NC=CC=C1N1C(=O)C2=CC=CC(NC(=O)CC=3C=C(C(Cl)=CC=3)C(F)(F)F)=C2C=C1 YAUDWMVXNVFABR-UHFFFAOYSA-N 0.000 description 2
• UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 2
• GRGQLGIWTINKKN-UHFFFAOYSA-N 2-cyclobutyl-5-nitroisoquinolin-1-one Chemical compound [O-][N+](=O)C1=CC=CC(C2=O)=C1C=CN2C1CCC1 GRGQLGIWTINKKN-UHFFFAOYSA-N 0.000 description 2
• NDMOACHYNICGRG-UHFFFAOYSA-N 2-cycloheptyl-n-(1-oxo-2-piperidin-4-ylisoquinolin-5-yl)acetamide Chemical compound C=1C=CC(C(N(C2CCNCC2)C=C2)=O)=C2C=1NC(=O)CC1CCCCCC1 NDMOACHYNICGRG-UHFFFAOYSA-N 0.000 description 2
• VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 2
• HPWYRFVFIAYCKQ-UHFFFAOYSA-N 5-amino-2-(1-azabicyclo[2.2.2]octan-3-yl)isoquinolin-1-one Chemical compound C1N(CC2)CCC2C1N(C1=O)C=CC2=C1C=CC=C2N HPWYRFVFIAYCKQ-UHFFFAOYSA-N 0.000 description 2
• IDWMBNCXGWPIID-UHFFFAOYSA-N 5-amino-2-(1h-pyrazol-5-yl)isoquinolin-1-one Chemical compound NC1=CC=CC(C2=O)=C1C=CN2C=1C=CNN=1 IDWMBNCXGWPIID-UHFFFAOYSA-N 0.000 description 2
• OLZFCMOUZBVVPB-UHFFFAOYSA-N 5-amino-2-(5-methyl-1h-pyrazol-3-yl)isoquinolin-1-one Chemical compound N1C(C)=CC(N2C(C3=CC=CC(N)=C3C=C2)=O)=N1 OLZFCMOUZBVVPB-UHFFFAOYSA-N 0.000 description 2
• MRIZWKYXPKYHFC-UHFFFAOYSA-N 5-amino-2-cyclobutylisoquinolin-1-one Chemical compound NC1=CC=CC(C2=O)=C1C=CN2C1CCC1 MRIZWKYXPKYHFC-UHFFFAOYSA-N 0.000 description 2
• OFELFQJDRMOISA-UHFFFAOYSA-N 5-aminoisochromen-1-one Chemical compound C1=COC(=O)C2=C1C(N)=CC=C2 OFELFQJDRMOISA-UHFFFAOYSA-N 0.000 description 2
• YPEYCILWOQHKLY-UHFFFAOYSA-N 5-nitro-2-(1h-pyrazol-5-yl)isoquinolin-1-one Chemical compound [O-][N+](=O)C1=CC=CC(C2=O)=C1C=CN2C=1C=CNN=1 YPEYCILWOQHKLY-UHFFFAOYSA-N 0.000 description 2
• UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
• 241000588832 Bordetella pertussis Species 0.000 description 2
• 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 2
• 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 2
• VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 2
• 102000000503 Collagen Type II Human genes 0.000 description 2
• 108010041390 Collagen Type II Proteins 0.000 description 2
• 235000004035 Cryptotaenia japonica Nutrition 0.000 description 2
• 244000146493 Cryptotaenia japonica Species 0.000 description 2
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
• 239000005977 Ethylene Substances 0.000 description 2
• 208000009386 Experimental Arthritis Diseases 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 208000035154 Hyperesthesia Diseases 0.000 description 2
• 102000004310 Ion Channels Human genes 0.000 description 2
• 108090000862 Ion Channels Proteins 0.000 description 2
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical group NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• 241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 2
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
• 206010033645 Pancreatitis Diseases 0.000 description 2
• 108010081690 Pertussis Toxin Proteins 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 102000002294 Purinergic P2X Receptors Human genes 0.000 description 2
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
• LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
• 206010040070 Septic Shock Diseases 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
• 150000008065 acid anhydrides Chemical class 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 206010053552 allodynia Diseases 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• 235000019270 ammonium chloride Nutrition 0.000 description 2
• 230000000202 analgesic effect Effects 0.000 description 2
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
• 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
• BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 2
• IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 125000001246 bromo group Chemical group Br* 0.000 description 2
• 239000007975 buffered saline Substances 0.000 description 2
• 150000001721 carbon Chemical group 0.000 description 2
• 229910002091 carbon monoxide Inorganic materials 0.000 description 2
• 230000006037 cell lysis Effects 0.000 description 2
• 229960001231 choline Drugs 0.000 description 2
• VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 2
• QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 2
• WDECIBYCCFPHNR-UHFFFAOYSA-N chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 2
• WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 2
• 206010009887 colitis Diseases 0.000 description 2
• 239000012230 colorless oil Substances 0.000 description 2
• VPUGDVKSAQVFFS-UHFFFAOYSA-N coronene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3)C4=C4C3=CC=C(C=C3)C4=C2C3=C1 VPUGDVKSAQVFFS-UHFFFAOYSA-N 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 125000000000 cycloalkoxy group Chemical group 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• 208000014793 distal colitis Diseases 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 239000000835 fiber Substances 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 210000003194 forelimb Anatomy 0.000 description 2
• 239000003205 fragrance Substances 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 2
• 229960000905 indomethacin Drugs 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 238000010253 intravenous injection Methods 0.000 description 2
• 229910052742 iron Inorganic materials 0.000 description 2
• 208000002551 irritable bowel syndrome Diseases 0.000 description 2
• 208000028867 ischemia Diseases 0.000 description 2
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
• GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 210000000265 leukocyte Anatomy 0.000 description 2
• 229910001425 magnesium ion Inorganic materials 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 230000014759 maintenance of location Effects 0.000 description 2
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
• 239000008108 microcrystalline cellulose Substances 0.000 description 2
• 229940016286 microcrystalline cellulose Drugs 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 239000003068 molecular probe Substances 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 125000002950 monocyclic group Chemical group 0.000 description 2
• 108010064578 myelin proteolipid protein (139-151) Proteins 0.000 description 2
• WPFPYUUTPGHYQS-UHFFFAOYSA-N n-(2-cyclopropyl-1-oxoisoquinolin-5-yl)-2-[2-fluoro-3-(trifluoromethyl)phenyl]acetamide Chemical compound C1=CC=C(C(F)(F)F)C(F)=C1CC(=O)NC1=CC=CC(C2=O)=C1C=CN2C1CC1 WPFPYUUTPGHYQS-UHFFFAOYSA-N 0.000 description 2
• FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
• 230000001537 neural effect Effects 0.000 description 2
• 230000000626 neurodegenerative effect Effects 0.000 description 2
• 230000007823 neuropathy Effects 0.000 description 2
• 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
• 239000012299 nitrogen atmosphere Substances 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
• OVPVGJFDFSJUIG-UHFFFAOYSA-N octalene Chemical compound C1=CC=CC=C2C=CC=CC=CC2=C1 OVPVGJFDFSJUIG-UHFFFAOYSA-N 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
• 230000010412 perfusion Effects 0.000 description 2
• YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
• RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
• LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 2
• 230000004962 physiological condition Effects 0.000 description 2
• GBROPGWFBFCKAG-UHFFFAOYSA-N picene Chemical compound C1=CC2=C3C=CC=CC3=CC=C2C2=C1C1=CC=CC=C1C=C2 GBROPGWFBFCKAG-UHFFFAOYSA-N 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 2
• BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
• 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 2
• 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 2
• NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
• JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
• 150000003248 quinolines Chemical class 0.000 description 2
• 239000000376 reactant Substances 0.000 description 2
• 239000000018 receptor agonist Substances 0.000 description 2
• 229940044601 receptor agonist Drugs 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 235000008790 seltzer Nutrition 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 230000036303 septic shock Effects 0.000 description 2
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
• 235000017557 sodium bicarbonate Nutrition 0.000 description 2
• 238000013222 sprague-dawley male rat Methods 0.000 description 2
• 238000012453 sprague-dawley rat model Methods 0.000 description 2
• 229910001220 stainless steel Inorganic materials 0.000 description 2
• 239000010935 stainless steel Substances 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 238000007619 statistical method Methods 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 229960001940 sulfasalazine Drugs 0.000 description 2
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 210000000966 temporal muscle Anatomy 0.000 description 2
• MOZOQDNRVPHFOO-UHFFFAOYSA-N tert-butyl 3-amino-4-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(N)C(O)C1 MOZOQDNRVPHFOO-UHFFFAOYSA-N 0.000 description 2
• 229930192474 thiophene Natural products 0.000 description 2
• 210000001685 thyroid gland Anatomy 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical group OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• 208000014001 urinary system disease Diseases 0.000 description 2
• 208000009935 visceral pain Diseases 0.000 description 2
• AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 2
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
• UXUFTKZYJYGMGO-CMCWBKRRSA-N (2s,3s,4r,5r)-5-[6-amino-2-[2-[4-[3-(2-aminoethylamino)-3-oxopropyl]phenyl]ethylamino]purin-9-yl]-n-ethyl-3,4-dihydroxyoxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(=O)NCCN)=CC=3)=NC(N)=C2N=C1 UXUFTKZYJYGMGO-CMCWBKRRSA-N 0.000 description 1
• KWMLJOLKUYYJFJ-GASJEMHNSA-N (2xi)-D-gluco-heptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C(O)=O KWMLJOLKUYYJFJ-GASJEMHNSA-N 0.000 description 1
• MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
• SLLFVLKNXABYGI-UHFFFAOYSA-N 1,2,3-benzoxadiazole Chemical compound C1=CC=C2ON=NC2=C1 SLLFVLKNXABYGI-UHFFFAOYSA-N 0.000 description 1
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
• STZHBULOYDCZET-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-amine;hydron;dichloride Chemical compound Cl.Cl.C1CC2C(N)CN1CC2 STZHBULOYDCZET-UHFFFAOYSA-N 0.000 description 1
• CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
• 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
• AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
• ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
• BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
• AAQTWLBJPNLKHT-UHFFFAOYSA-N 1H-perimidine Chemical compound N1C=NC2=CC=CC3=CC=CC1=C32 AAQTWLBJPNLKHT-UHFFFAOYSA-N 0.000 description 1
• JAAGHUBILRENEC-UHFFFAOYSA-N 1h-benzo[g]indazole Chemical compound C1=CC2=CC=CC=C2C2=C1C=NN2 JAAGHUBILRENEC-UHFFFAOYSA-N 0.000 description 1
• JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical compound NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 1
• PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
• VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
• BHAWOWCKVUITOE-UHFFFAOYSA-N 2-(1-adamantyl)-n-[1-oxo-2-(1h-pyrazol-5-yl)isoquinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC(C2=O)=C1C=CN2C1=CC=NN1 BHAWOWCKVUITOE-UHFFFAOYSA-N 0.000 description 1
• AKUAECKBERVFOI-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-(1-azabicyclo[2.2.2]octan-3-yl)-1-oxoisoquinolin-5-yl]acetamide Chemical compound C1N(CC2)CCC2C1N(C1=O)C=CC2=C1C=CC=C2NC(=O)CC1(C2)CC(C3)CC2CC3C1 AKUAECKBERVFOI-UHFFFAOYSA-N 0.000 description 1
• AOTQGWFNFTVXNQ-UHFFFAOYSA-N 2-(1-adamantyl)acetic acid Chemical compound C1C(C2)CC3CC2CC1(CC(=O)O)C3 AOTQGWFNFTVXNQ-UHFFFAOYSA-N 0.000 description 1
• HVLZFDHYIVGZEY-UHFFFAOYSA-N 2-(2-adamantyl)-n-[2-(1-azabicyclo[2.2.2]octan-3-yl)-1-oxoisoquinolin-5-yl]acetamide Chemical compound C1N(CC2)CCC2C1N(C1=O)C=CC2=C1C=CC=C2NC(=O)CC1C(C2)CC3CC2CC1C3 HVLZFDHYIVGZEY-UHFFFAOYSA-N 0.000 description 1
• LISKQYCKJZRNLW-UHFFFAOYSA-N 2-(2-fluoropyridin-3-yl)-5-nitroisoquinolin-1-one Chemical compound [O-][N+](=O)C1=CC=CC(C2=O)=C1C=CN2C1=CC=CN=C1F LISKQYCKJZRNLW-UHFFFAOYSA-N 0.000 description 1
• ONTSTGLBCASTJD-UHFFFAOYSA-N 2-(2-methylpyridin-3-yl)-5-nitroisoquinolin-1-one Chemical compound CC1=NC=CC=C1N1C(=O)C2=CC=CC([N+]([O-])=O)=C2C=C1 ONTSTGLBCASTJD-UHFFFAOYSA-N 0.000 description 1
• PSQNJHVIVDSIJG-UHFFFAOYSA-N 2-(4-methylpyridin-3-yl)-5-nitroisoquinolin-1-one Chemical compound CC1=CC=NC=C1N1C(=O)C2=CC=CC([N+]([O-])=O)=C2C=C1 PSQNJHVIVDSIJG-UHFFFAOYSA-N 0.000 description 1
• PKZJJBIIHOJIBV-UHFFFAOYSA-N 2-(5-methyl-1h-pyrazol-3-yl)-5-nitroisoquinolin-1-one Chemical compound N1C(C)=CC(N2C(C3=CC=CC(=C3C=C2)[N+]([O-])=O)=O)=N1 PKZJJBIIHOJIBV-UHFFFAOYSA-N 0.000 description 1
• GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
• IZXLNEHPKQVCAE-UHFFFAOYSA-N 2-[2-fluoro-3-(trifluoromethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(F)(F)F)=C1F IZXLNEHPKQVCAE-UHFFFAOYSA-N 0.000 description 1
• GHGHYRAPLHZMQW-UHFFFAOYSA-N 2-[4-chloro-3-(trifluoromethyl)phenyl]-n-[2-(4-hydroxypyrrolidin-3-yl)-1-oxoisoquinolin-5-yl]acetamide Chemical compound OC1CNCC1N1C(=O)C2=CC=CC(NC(=O)CC=3C=C(C(Cl)=CC=3)C(F)(F)F)=C2C=C1 GHGHYRAPLHZMQW-UHFFFAOYSA-N 0.000 description 1
• VPNHDEXOQSXYNJ-UHFFFAOYSA-N 2-[4-chloro-3-(trifluoromethyl)phenyl]-n-[2-(4-hydroxypyrrolidin-3-yl)-1-oxoisoquinolin-5-yl]acetamide;hydrochloride Chemical class Cl.OC1CNCC1N1C(=O)C2=CC=CC(NC(=O)CC=3C=C(C(Cl)=CC=3)C(F)(F)F)=C2C=C1 VPNHDEXOQSXYNJ-UHFFFAOYSA-N 0.000 description 1
• IJUSUZDDYJWSET-UHFFFAOYSA-N 2-[4-chloro-3-(trifluoromethyl)phenyl]-n-[2-(5-methyl-1h-pyrazol-3-yl)-1-oxoisoquinolin-5-yl]propanamide Chemical compound C=1C=C(Cl)C(C(F)(F)F)=CC=1C(C)C(=O)NC1=CC=CC(C2=O)=C1C=CN2C=1C=C(C)NN=1 IJUSUZDDYJWSET-UHFFFAOYSA-N 0.000 description 1
• DQNWKASPZFJVMJ-UHFFFAOYSA-N 2-cycloheptylacetic acid Chemical compound OC(=O)CC1CCCCCC1 DQNWKASPZFJVMJ-UHFFFAOYSA-N 0.000 description 1
• QVDACIZNNNFTBO-UHFFFAOYSA-N 2-fluoropyridin-3-amine Chemical compound NC1=CC=CN=C1F QVDACIZNNNFTBO-UHFFFAOYSA-N 0.000 description 1
• UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
• ZSFPJJJRNUZCEV-UHFFFAOYSA-N 2-methylpyridin-3-amine Chemical compound CC1=NC=CC=C1N ZSFPJJJRNUZCEV-UHFFFAOYSA-N 0.000 description 1
• 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
• MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
• XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
• HLLSOEKIMZEGFV-UHFFFAOYSA-N 4-(dibutylsulfamoyl)benzoic acid Chemical compound CCCCN(CCCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 HLLSOEKIMZEGFV-UHFFFAOYSA-N 0.000 description 1
• RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
• IBKMZYWDWWIWEL-UHFFFAOYSA-N 4-methylpyridin-3-amine Chemical compound CC1=CC=NC=C1N IBKMZYWDWWIWEL-UHFFFAOYSA-N 0.000 description 1
• FYTLHYRDGXRYEY-UHFFFAOYSA-N 5-Methyl-3-pyrazolamine Chemical compound CC=1C=C(N)NN=1 FYTLHYRDGXRYEY-UHFFFAOYSA-N 0.000 description 1
• WJBBXCPUHSVERI-UHFFFAOYSA-N 5-amino-2-(2-fluoropyridin-3-yl)isoquinolin-1-one Chemical compound NC1=CC=CC(C2=O)=C1C=CN2C1=CC=CN=C1F WJBBXCPUHSVERI-UHFFFAOYSA-N 0.000 description 1
• MDXVPBHGSHEPMV-UHFFFAOYSA-N 5-amino-2-(2-methoxypyridin-3-yl)isoquinolin-1-one Chemical compound COC1=NC=CC=C1N1C(=O)C2=CC=CC(N)=C2C=C1 MDXVPBHGSHEPMV-UHFFFAOYSA-N 0.000 description 1
• BZJKIXIEKPYBSU-UHFFFAOYSA-N 5-amino-2-(2-methylpyridin-3-yl)isoquinolin-1-one Chemical compound CC1=NC=CC=C1N1C(=O)C2=CC=CC(N)=C2C=C1 BZJKIXIEKPYBSU-UHFFFAOYSA-N 0.000 description 1
• NHLGFGAWXSTVRA-UHFFFAOYSA-N 5-amino-2-(4-methylpyridin-3-yl)isoquinolin-1-one Chemical compound CC1=CC=NC=C1N1C(=O)C2=CC=CC(N)=C2C=C1 NHLGFGAWXSTVRA-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 206010002329 Aneurysm Diseases 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
• 238000011731 BALB/cByJ (JAX™ mouse strain) Methods 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 1
• HNZUXXPBGOUANO-UHFFFAOYSA-N C1(CC1)N1C(C2=CC=CC(=C2C=C1)[N+](=O)[O-])=O.NC1=C2C=CN(C(C2=CC=C1)=O)C1CC1 Chemical compound C1(CC1)N1C(C2=CC=CC(=C2C=C1)[N+](=O)[O-])=O.NC1=C2C=CN(C(C2=CC=C1)=O)C1CC1 HNZUXXPBGOUANO-UHFFFAOYSA-N 0.000 description 1
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
• JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
• 0 CCNC(C)*(C)=C Chemical compound CCNC(C)*(C)=C 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
• WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 101150065749 Churc1 gene Proteins 0.000 description 1
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
• HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical group OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
• 108020003215 DNA Probes Proteins 0.000 description 1
• 239000003298 DNA probe Substances 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 206010061819 Disease recurrence Diseases 0.000 description 1
• 206010013647 Drowning Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 241000764238 Isis Species 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
• 206010023799 Large intestinal ulcer Diseases 0.000 description 1
• 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
• 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
• 244000246386 Mentha pulegium Species 0.000 description 1
• 235000016257 Mentha pulegium Nutrition 0.000 description 1
• 235000004357 Mentha x piperita Nutrition 0.000 description 1
• 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
• 102000055324 Myelin Proteolipid Human genes 0.000 description 1
• 101710094913 Myelin proteolipid protein Proteins 0.000 description 1
• ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
• 208000028389 Nerve injury Diseases 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
• 239000006057 Non-nutritive feed additive Substances 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• QGCJRGWOWRVTKJ-UHFFFAOYSA-N O=C1OC=Cc2c1cccc2N=O Chemical compound O=C1OC=Cc2c1cccc2N=O QGCJRGWOWRVTKJ-UHFFFAOYSA-N 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 108091075598 P2X receptor family Proteins 0.000 description 1
• 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
• NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
• 229910052777 Praseodymium Inorganic materials 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 102100038239 Protein Churchill Human genes 0.000 description 1
• 108010000836 Purinergic P2X Receptors Proteins 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
• 239000012979 RPMI medium Substances 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 238000000692 Student's t-test Methods 0.000 description 1
• 244000028419 Styrax benzoin Species 0.000 description 1
• 235000000126 Styrax benzoin Nutrition 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 235000008411 Sumatra benzointree Nutrition 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• SLGBZMMZGDRARJ-UHFFFAOYSA-N Triphenylene Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC=C3C2=C1 SLGBZMMZGDRARJ-UHFFFAOYSA-N 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 241000269370 Xenopus <genus> Species 0.000 description 1
• QVXFGVVYTKZLJN-KHPPLWFESA-N [(z)-hexadec-7-enyl] acetate Chemical compound CCCCCCCC\C=C/CCCCCCOC(C)=O QVXFGVVYTKZLJN-KHPPLWFESA-N 0.000 description 1
• DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
• UXGLUQUKXIAWEY-UHFFFAOYSA-N [N+](=O)([O-])C1=C2C=COC(C2=CC=C1)=O.C1(CC1)N1C(C2=CC=CC(=C2C=C1)[N+](=O)[O-])=O Chemical compound [N+](=O)([O-])C1=C2C=COC(C2=CC=C1)=O.C1(CC1)N1C(C2=CC=CC(=C2C=C1)[N+](=O)[O-])=O UXGLUQUKXIAWEY-UHFFFAOYSA-N 0.000 description 1
• 210000000683 abdominal cavity Anatomy 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 238000002679 ablation Methods 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
• SQFPKRNUGBRTAR-UHFFFAOYSA-N acephenanthrylene Chemical group C1=CC(C=C2)=C3C2=CC2=CC=CC=C2C3=C1 SQFPKRNUGBRTAR-UHFFFAOYSA-N 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical class C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
• 230000001464 adherent effect Effects 0.000 description 1
• GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 229910001413 alkali metal ion Inorganic materials 0.000 description 1
• 125000004450 alkenylene group Chemical group 0.000 description 1
• 125000000033 alkoxyamino group Chemical group 0.000 description 1
• 125000002877 alkyl aryl group Chemical group 0.000 description 1
• 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 125000006598 aminocarbonylamino group Chemical group 0.000 description 1
• 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 1
• DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 230000003444 anaesthetic effect Effects 0.000 description 1
• 229940035676 analgesics Drugs 0.000 description 1
• 238000000540 analysis of variance Methods 0.000 description 1
• 239000003994 anesthetic gas Substances 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 239000000730 antalgic agent Substances 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 210000000612 antigen-presenting cell Anatomy 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 239000012736 aqueous medium Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• BVUSIQTYUVWOSX-UHFFFAOYSA-N arsindole Chemical compound C1=CC=C2[As]C=CC2=C1 BVUSIQTYUVWOSX-UHFFFAOYSA-N 0.000 description 1
• 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
• KNNXFYIMEYKHBZ-UHFFFAOYSA-N as-indacene Chemical compound C1=CC2=CC=CC2=C2C=CC=C21 KNNXFYIMEYKHBZ-UHFFFAOYSA-N 0.000 description 1
• 239000000305 astragalus gummifer gum Substances 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 229940092714 benzenesulfonic acid Drugs 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 229960002130 benzoin Drugs 0.000 description 1
• DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
• GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
• DPECLNSLLIQJJO-UHFFFAOYSA-M benzyl-diethyl-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethyl]azanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1C[N+](CC)(CC)CCOC1=CC=C(C(C)(C)CC(C)(C)C)C=C1 DPECLNSLLIQJJO-UHFFFAOYSA-M 0.000 description 1
• WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
• 229960004853 betadex Drugs 0.000 description 1
• 229940064804 betadine Drugs 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 230000001488 breeding effect Effects 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 229910052792 caesium Inorganic materials 0.000 description 1
• TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical group [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 125000004112 carboxyamino group Chemical group [H]OC(=O)N([H])[*] 0.000 description 1
• 230000004706 cardiovascular dysfunction Effects 0.000 description 1
• 210000001715 carotid artery Anatomy 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 239000008004 cell lysis buffer Substances 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 210000001627 cerebral artery Anatomy 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 235000013985 cinnamic acid Nutrition 0.000 description 1
• 229930016911 cinnamic acid Natural products 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 230000019771 cognition Effects 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 150000001907 coumarones Chemical class 0.000 description 1
• 239000006059 cover glass Substances 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• KZZKOVLJUKWSKX-UHFFFAOYSA-N cyclobutanamine Chemical compound NC1CCC1 KZZKOVLJUKWSKX-UHFFFAOYSA-N 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
• 230000001461 cytolytic effect Effects 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000018044 dehydration Effects 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• VRRJYERADSBBPI-JIZZDEOASA-L dicesium;(2s)-2-aminobutanedioate Chemical compound [Cs+].[Cs+].[O-]C(=O)[C@@H](N)CC([O-])=O VRRJYERADSBBPI-JIZZDEOASA-L 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• YKZPPPNXRZHVGX-PXYKVGKMSA-L dipotassium;(2s)-2-aminobutanedioate;hydron;hydrate Chemical compound [H+].[H+].O.[K+].[K+].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O YKZPPPNXRZHVGX-PXYKVGKMSA-L 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000002224 dissection Methods 0.000 description 1
• 210000004921 distal colon Anatomy 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical group CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 230000008406 drug-drug interaction Effects 0.000 description 1
• 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 150000002085 enols Chemical class 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
• LBAQSKZHMLAFHH-UHFFFAOYSA-N ethoxyethane;hydron;chloride Chemical compound Cl.CCOCC LBAQSKZHMLAFHH-UHFFFAOYSA-N 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
• 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
• 210000001105 femoral artery Anatomy 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 238000003818 flash chromatography Methods 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 235000011087 fumaric acid Nutrition 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 238000010448 genetic screening Methods 0.000 description 1
• 239000000174 gluconic acid Chemical group 0.000 description 1
• 235000012208 gluconic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Chemical group 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 229960002743 glutamine Drugs 0.000 description 1
• 230000003370 grooming effect Effects 0.000 description 1
• 235000019382 gum benzoic Nutrition 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 125000005241 heteroarylamino group Chemical group 0.000 description 1
• QSQIGGCOCHABAP-UHFFFAOYSA-N hexacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC6=CC=CC=C6C=C5C=C4C=C3C=C21 QSQIGGCOCHABAP-UHFFFAOYSA-N 0.000 description 1
• PKIFBGYEEVFWTJ-UHFFFAOYSA-N hexaphene Chemical compound C1=CC=C2C=C3C4=CC5=CC6=CC=CC=C6C=C5C=C4C=CC3=CC2=C1 PKIFBGYEEVFWTJ-UHFFFAOYSA-N 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 235000001050 hortel pimenta Nutrition 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 150000004678 hydrides Chemical class 0.000 description 1
• 239000008309 hydrophilic cream Substances 0.000 description 1
• 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
• 238000007654 immersion Methods 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 229940125721 immunosuppressive agent Drugs 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 238000012739 integrated shape imaging system Methods 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
• ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 150000003951 lactams Chemical class 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 208000014987 limb edema Diseases 0.000 description 1
• 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 210000001853 liver microsome Anatomy 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 238000011670 long-evans rat Methods 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 231100000053 low toxicity Toxicity 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 230000002101 lytic effect Effects 0.000 description 1
• 229940096405 magnesium cation Drugs 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 229960002510 mandelic acid Drugs 0.000 description 1
• 201000006512 mast cell neoplasm Diseases 0.000 description 1
• 208000006971 mastocytoma Diseases 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• CRZGFIMLHZTLGT-UHFFFAOYSA-N methyl 2-methyl-3-nitrobenzoate Chemical compound COC(=O)C1=CC=CC([N+]([O-])=O)=C1C CRZGFIMLHZTLGT-UHFFFAOYSA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
• 229940012189 methyl orange Drugs 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
• 229960001047 methyl salicylate Drugs 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
• 230000008764 nerve damage Effects 0.000 description 1
• 239000003176 neuroleptic agent Substances 0.000 description 1
• 230000000701 neuroleptic effect Effects 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• HKKDKUMUWRTAIA-UHFFFAOYSA-N nitridooxidocarbon(.) Chemical compound [O]C#N HKKDKUMUWRTAIA-UHFFFAOYSA-N 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• VLZLOWPYUQHHCG-UHFFFAOYSA-N nitromethylbenzene Chemical compound [O-][N+](=O)CC1=CC=CC=C1 VLZLOWPYUQHHCG-UHFFFAOYSA-N 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• NJPPVKZQTLUDBO-UHFFFAOYSA-N novaluron Chemical compound C1=C(Cl)C(OC(F)(F)C(OC(F)(F)F)F)=CC=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F NJPPVKZQTLUDBO-UHFFFAOYSA-N 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
• PFTXKXWAXWAZBP-UHFFFAOYSA-N octacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC6=CC7=CC8=CC=CC=C8C=C7C=C6C=C5C=C4C=C3C=C21 PFTXKXWAXWAZBP-UHFFFAOYSA-N 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000003883 ointment base Substances 0.000 description 1
• 238000001543 one-way ANOVA Methods 0.000 description 1
• 210000000287 oocyte Anatomy 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 238000003305 oral gavage Methods 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Chemical group OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 208000010713 partial hind limb paralysis Diseases 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• PMJHHCWVYXUKFD-UHFFFAOYSA-N penta-1,3-diene Chemical compound CC=CC=C PMJHHCWVYXUKFD-UHFFFAOYSA-N 0.000 description 1
• SLIUAWYAILUBJU-UHFFFAOYSA-N pentacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC=CC=C5C=C4C=C3C=C21 SLIUAWYAILUBJU-UHFFFAOYSA-N 0.000 description 1
• JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
• GUVXZFRDPCKWEM-UHFFFAOYSA-N pentalene Chemical compound C1=CC2=CC=CC2=C1 GUVXZFRDPCKWEM-UHFFFAOYSA-N 0.000 description 1
• JQQSUOJIMKJQHS-UHFFFAOYSA-N pentaphene Chemical compound C1=CC=C2C=C3C4=CC5=CC=CC=C5C=C4C=CC3=CC2=C1 JQQSUOJIMKJQHS-UHFFFAOYSA-N 0.000 description 1
• 229960001412 pentobarbital Drugs 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 description 1
• CSHWQDPOILHKBI-UHFFFAOYSA-N peryrene Natural products C1=CC(C2=CC=CC=3C2=C2C=CC=3)=C3C2=CC=CC3=C1 CSHWQDPOILHKBI-UHFFFAOYSA-N 0.000 description 1
• 235000019271 petrolatum Nutrition 0.000 description 1
• 239000008024 pharmaceutical diluent Substances 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• NQFOGDIWKQWFMN-UHFFFAOYSA-N phenalene Chemical compound C1=CC([CH]C=C2)=C3C2=CC=CC3=C1 NQFOGDIWKQWFMN-UHFFFAOYSA-N 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
• 239000002985 plastic film Substances 0.000 description 1
• 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 238000002600 positron emission tomography Methods 0.000 description 1
• 230000002980 postoperative effect Effects 0.000 description 1
• 229940068988 potassium aspartate Drugs 0.000 description 1
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical class [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
• 239000008057 potassium phosphate buffer Substances 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 238000002203 pretreatment Methods 0.000 description 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 125000006410 propenylene group Chemical group 0.000 description 1
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• LNKHTYQPVMAJSF-UHFFFAOYSA-N pyranthrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC3=C(C=CC=C4)C4=CC4=CC=C1C2=C34 LNKHTYQPVMAJSF-UHFFFAOYSA-N 0.000 description 1
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
• BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 1
• 229960001327 pyridoxal phosphate Drugs 0.000 description 1
• 229940107700 pyruvic acid Drugs 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000010410 reperfusion Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000029058 respiratory gaseous exchange Effects 0.000 description 1
• 201000006845 reticulosarcoma Diseases 0.000 description 1
• 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• WEMQMWWWCBYPOV-UHFFFAOYSA-N s-indacene Chemical compound C=1C2=CC=CC2=CC2=CC=CC2=1 WEMQMWWWCBYPOV-UHFFFAOYSA-N 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 239000008117 stearic acid Chemical group 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000002889 sympathetic effect Effects 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 238000012353 t test Methods 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 238000003419 tautomerization reaction Methods 0.000 description 1
• YEBDZDMYLQHGGZ-UHFFFAOYSA-N tert-butyl 2,5-dihydropyrrole-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC=CC1 YEBDZDMYLQHGGZ-UHFFFAOYSA-N 0.000 description 1
• CSWBTQKOSPXYIE-UHFFFAOYSA-N tert-butyl 3-azido-4-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(O)C(N=[N+]=[N-])C1 CSWBTQKOSPXYIE-UHFFFAOYSA-N 0.000 description 1
• KRYJSYYHAUULLB-UHFFFAOYSA-N tert-butyl 4-(5-amino-1-oxoisoquinolin-2-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1C(=O)C2=CC=CC(N)=C2C=C1 KRYJSYYHAUULLB-UHFFFAOYSA-N 0.000 description 1
• LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 1
• 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
• CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical group CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
• CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
• 150000003536 tetrazoles Chemical class 0.000 description 1
• VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
• 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
• GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 1
• FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Substances O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 229940100611 topical cream Drugs 0.000 description 1
• 229940100615 topical ointment Drugs 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 150000003852 triazoles Chemical class 0.000 description 1
• 125000005580 triphenylene group Chemical group 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 238000007492 two-way ANOVA Methods 0.000 description 1
• 210000001364 upper extremity Anatomy 0.000 description 1
• 150000003672 ureas Chemical class 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000003871 white petrolatum Substances 0.000 description 1
• 239000000230 xanthan gum Substances 0.000 description 1
• 235000010493 xanthan gum Nutrition 0.000 description 1
• 229920001285 xanthan gum Polymers 0.000 description 1
• 229940082509 xanthan gum Drugs 0.000 description 1